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Abstract
Background: Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes involved in extracellular matrix
(ECM) homeostasis. MMPs have been an attractive pharmacological target for a number of indications. However,
development has been hampered by the propensity of compounds targeting these enzymes to cause connective-
tissue pathologies. The broad-spectrum MMP-inhibitor (MMPi) AZM551248 has been shown to induce such effects
in the dog. Histopathological changes were consistent with fibrodysplasia (FD), characterised by fibroblast
proliferation and the deposition of collagen in the subcutaneous tissues. We conducted a time-course study
administering 20mg/kg/day AZM551248 between 4 and 17 days. Cervical subcutaneous tissue and plasma were
sampled during the time-course. miRNA expression profiles in subcutaneous skin specimens following the
administration of AZM551248 were determined by high-throughput-sequencing.
Results: An increasing number of miRNAs were differentially expressed compared with vehicle treated control
animals as the study progressed. Several of these were members of the miR-200 family and were significantly
attenuated in response to MMPi. As the severity of FD increased at the later time-points, other miRNAs associated
with TGFβ synthesis and regulation of the acute inflammatory response were modulated. Evidence indicative of
epithelial to mesenchymal transition was present at all study time points. Receiver operator curve (ROC) analysis
revealed that miR-21 expression in the cervical subcutaneous tissue was a sensitive and specific biomarker of FD
incidence.
Conclusions: Our data reveal significant perturbations in canine skin miRNA expression in response to MMPi
administration. Furthermore, we have identified dysregulated miRNAs that are associated with processes relevant to
the key histopathological events of MMPi-induced FD.
Background
Matrix metalloproteinases (MMPs) are a family of ap-
proximately 30 proteolytic enzymes involved in extracel-
lular matrix (ECM) homeostasis in normal physiology,
wound-healing [1] and in various pathologies. The in-
volvement of MMPs in pathology may be grouped into
those involved in tissue destruction; for example in
rheumatoid and osteoarthritis, ulceration and periodon-
tal disease; those promoting fibrosis in fibrotic lung dis-
ease, cirrhosis and multiple sclerosis; and those that
weaken the matrix as seen in cardiomyopathies and
some dermatological conditions [2]. MMPs have been
the subject of much investigation surrounding their
potential as suitable pharmacological targets for various
disease states. The first disease target of MMP inhibition
was rheumatoid arthritis [2]; however in recent years
matrix metalloproteinase inhibition (MMPi) has been
considered for various other conditions including osteo-
arthritis [3], cardiovascular disease [4] and cancer [5].
Thus far, the development of many MMPis has been
limited by their tendency to elicit various undesirable con-
nective tissue pathologies in both preclinical animal
models and in the clinic, at efficacious blood concentra-
tions. In man, these side effects present as musculoskeletal
syndrome (MSS), a disorder originating in the shoulder or
hands, characterised by musculoskeletal pain and inflam-
mation leading to reduced joint mobility [6]. In pre-
clinical animal models, tissue pathologies tend to occur
following 14 to 21 days administration of MMPi, appear
to be dose-dependent, and are generally reversible on
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discontinuation of MMPi therapy [7]. In the rodent, clin-
ical signs following MMPi administration include reduced
movement, reluctance to rest on the hind limbs, and in-
creased hind paw volume. Histological assessment reveals
several characteristic findings including growth plate
thickening, synovial hyperplasia, soft tissue fibroplasias
and lymphocyte infiltrates [8]. These features associ-
ated with MMPi administration have been collectively
termed "fibrodysplasia" [9]. In the canine, the most
sensitive site for MMPi- induced fibrodysplasia is the
subcuticular connective tissue which is affected from
11 days post-treatment, although other musculoskel-
etal tissues are extensively involved, as with other spe-
cies, as administration continues [9].
Further compounding the liability of MMPis to elicit FD
is the current lack of functional biomarkers suitable for
early in vivo screening. Indeed, to date most studies have
concentrated on the effects of MMPis at the end-of-treat-
ment once FD is manifest, and following termination,
using a variety of time-intensive histological techniques
[6]. It is this inability to screen for early FD effects in vivo
that led us to consider alternative classes of biomarkers.
One class of potentially informative biomarkers is the
microRNA family (miRNA). These short, non-protein-
coding RNAs modulate protein translation from specific
mRNAs [10]. They have been implicated in a variety of
biological processes and are reported to regulate the ma-
jority of genes in the human genome [11]. Similar to many
messenger RNAs (mRNA), miRNAs exhibit marked tissue
specificity [12], and appear to be dysregulated in response
to specific pathological conditions [10]. Perhaps most sig-
nificant is the finding that miRNAs are readily detectable
in various biological fluids (including plasma and serum)
[13] and remain stable during routine clinical processing
[14], paving the way for their use as novel biomarkers.
Herein, we report a global assessment of miRNA expres-
sion in the cervical subcutaneous tissue of dogs treated
with the broad-spectrum MMPi AZM551248 at a dosage
of 20mg/kg/day for between 4 and 17 days. This dose has
been previously shown to induce subcutaneous FD follow-
ing 17 days of administration in a pilot study involving two
female beagle dogs (data not shown). A detailed histo-
pathological report of the changes associated with FD in
this study was published first in 2009 [9] and described a
phased onset of FD in the cervical subcutaneous tissue fol-
lowing 11 days administration of AZM551248. More re-
cently, an analysis of the changes in messenger RNA
(mRNA) expression and in MMP activity following
AZM551248 administration was reported [15]. The experi-
mental aims of this study were to (I) further characterise
the molecular events directly preceding the initiation and
during the development of MMPi-induced FD in the same
study subjects by considering miRNA dysregulation, and
(II) to identify whether any miRNA(s) have the potential to
serve as informative biomarkers of FD, thus addressing a
current unmet need in the safety assessment of MMPis.
Results
In vivo histopathological analysis and plasma procollagen
type III aminoterminal peptide (PIIINP) determination
The full range of histopathological changes observed in
response to MMPi administration have been discussed in
detail elsewhere [9]. Briefly, animals receiving vehicle or
MMPi for 4 days showed no evidence of fibrodysplastic
change. One animal showed evidence of fibrodysplasia fol-
lowing 8 days (n = 5) administration, 2 following 11 days
administration (n = 5) whilst all animals showed varying
severities of FD following administration of MMPi for 14
or 17 days (n = 5 respectively).
Plasma procollagen type III aminoterminal peptide
(PIIINP) has been reported previously as a prospective
biomarker of various fibrotic pathologies affecting the
skin [16], liver [17] and heart [18]. Plasma PIIINP con-
centration was unaffected by MMPi administration up
to 8 days in duration when compared to vehicle treated
controls. Administration of MMPi for 11 days resulted
in elevated plasma PIIINP concentrations compared with
vehicle treated controls (Figure 1). This elevation in
plasma PIIINP concentration was coincident with the
first histological evidence of FD and was maintained
until the study end point at 17 days. Plasma PIIINP con-
centration was found to be highly correlated with the
histopathological grade of FD in the cervical subcutane-
ous tissue (r = 0.73) as determined by the Pearson prod-
uct–moment correlation coefficient (data not shown).
Figure 1 Changes in plasma PIIINP concentration in response
to AZM551248 administration. Data are mean plasma PIIINP
concentration (μg/l plasma) following administration of vehicle
(control) or MMPi for 4, 8, 11, 14 and 17 days + S.E.M (n = 5). Data are
analysed by one-way analysis of variance with Dunnett's post hoc test
(comparing all experimental groups to vehicle) where P < 0.05; ***
denotes P < 0.001.
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Global miRNA profiling
An average of 5,800,000 ± 400,000 total reads with an
average length of 21.83 ± 0.03 bases (mean ± standard
error of the mean) were obtained from each cervical sub-
cutaneous lesion. Significant changes in miRNA abun-
dance following 4, 8, 11, 14 and 17 days administration
of MMPi are detailed in Figure 2A, and a comprehensive
set of miRNA expression data are included within
Additional file 1. The number of significantly regulated
miRNAs relative to vehicle treated controls appeared
to increase over time with the exception of animals
treated for 4 days which exhibited more changes than
those treated for 8 or 11 days (Day 4: 13 miRNAs; Day 8:
6 miRNAs; Day 11: 11 miRNAs). The time point(s) at
which each miRNA was dysregulated are presented in the
form of a 5-order Venn diagram (Figure 2B). A selection
of miRNA changes were validated by reverse transcriptase
real-time PCR, results of which are presented in Figure 3.
In order to explore any potential relationships between
the various miRNAs regulated at each time point and
their potential regulatory mechanisms, results of gen-
omic clustering analyses were obtained from miRBase
V16.0. These data describe miRNAs within 10 kilo-
bases (Kb) of each other on the canine genome, and
therefore identify miRNAs with the potential to be
transcriptionally co-regulated. Clusters of miRNAs are
denoted in Figure 2C.
Initiating events - miRNA modulation following 4 days
AZM551248 administration
Despite the lack of histopathological changes in the cer-
vical subcutaneous tissue following 4 days administra-
tion of AZM551248, 13 miRNAs were found to be
differentially expressed compared to vehicle treated con-
trol animals (Figure 2A). Of these, 7 miRNAs were
found to be members of the miR-200 family - a collec-
tion of miRNAs grouped by their functional similarities
and location on the genome.
In order to explore the potential role of these miRNAs
in the initiation of pre-histopathological changes in re-
sponse to MMPi administration, they were considered in
the context of changes in the mRNA environment at this
time using a concatenated dataset comprising 13 miRNAs
and 221 mRNAs. The concatenated dataset was prepared
by combining both mRNA and miRNA expression data
(see materials and methods section). Previous reports
have suggested that the early changes in response to
MMPi administration were associated with the activa-
tion of transcription factors Sp1, RelA and STAT1
[15]. The changes in mRNA and miRNA expression
were therefore presented in the context of Sp1, RelA
and STAT1 activation by including these transcription
factors within the pathway analysis. Functions of the
top two scoring gene networks and associated gene
network diagrams are presented in Figure 4 (Day 4),
and Additional file 2 (Days 8–14).
Four days administration of AZM551248 was associ-
ated with regulation of gene networks involved in (1)
Cancer, Endocrine System Disorders, Reproductive Sys-
tem Disease and (2) Post-translational Modification, Pro-
tein Degradation, Protein Synthesis. Analysis of the most
significant gene regulatory networks (Figure 4) revealed
a complex interplay between several messenger RNAs,
transcription factors, and the dysregulated miRNAs. It is
noteworthy that the top regulatory network (Figure 4A)
included 4 out of the 13 differentially regulated miRNAs
identified at day 4 (all 4 were down-regulated) and that
there were extensive predicted interactions with the
transcription factors Sp1, RelA and STAT1. The second
most significant regulatory network included many fac-
tors involved in extracellular matrix remodelling includ-
ing MMPs 1, 2 and 3, and the proteases dipeptidyl
peptidase IV (DPP4) and Cathepsin K. Of interest was
the finding that miRNAs 31, 200a*, 203 and 429 (in-
cluded in Figures 4A/4C) were predicted to target Sp1
suggesting their involvement in the negative regulation
of this transcriptional regulator.
Disease development and progression - miRNA modulation
from day 8 to day 17
AZM551248 administration for a duration of 8 days saw
evidence of histological changes in the cervical subcuta-
neous tissue consistent with FD, however this was lim-
ited to a single animal (for which sequencing data was
collected), with the remaining 4 animals appearing histo-
logically normal. In confirmation of this limited change
in phenotype, this time point was associated with just 6
dysregulated miRNAs (Figure 2A), half of which were
maintained from day 4 suggesting that molecular modu-
lation at day 4 may be key to the initiation of
fibrodysplasia. Novel findings at day 8 included the up-
regulation of cfa-miR-34c*, and the down-regulation of
cfa-miR-497* and cfa-miR-210. Combined miRNA and
mRNA pathway analysis (comprising 6 miRNAs and 228
mRNAs) revealed that eight days administration of
MMPi was associated with regulation of gene networks
involved in (1) Post-translational Modification, Protein
Degradation, Protein Synthesis (as previously identified
at day 4), and (2) Hereditary Disorder, Skeletal and Mus-
cular Disorders, Cellular Development and Cancer
(Additional file 2). Both gene networks highlighted the
involvement of transcription factors Sp1, RelA and
STAT1. However, miRNA involvement was limited to
cfa-miR-200a* which had been down-regulated previ-
ously at day 4.
AZM551248 administration for 11 to 17 days was as-
sociated with an increase in histological evidence of FD
in the cervical subcutaneous tissue, and in the number
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of significantly dysregulated miRNAs (Figure 2A). Day
11 was associated with 11 dysregulated miRNAs of
which 7 had not been dysregulated at the earlier time
points, and marked the appearance of cfa-miR-21 as the
most highly expressed miRNA. Clustering analysis
revealed that two of these miRNAs were located within
10Kb on canine chromosome 7. Combined pathway ana-
lysis (comprising 11 miRNAs and 505 mRNAs) revealed
that eleven days administration of AZM551248 was as-
sociated with the regulation of gene networks involved
(See figure on previous page.)
Figure 2 Assessment of miRNAs differentially expressed in response to AZM551248 administration. (A) Heat map generated from high-
throughput sequencing data (miRNA-seq) showing miRNA expression changes in the cervical subcutaneous tissue in response to AZM551248 (n =
4 for days 4, 8, 11, 14 and 17 respectively). Data are the miRNA identifier (miRBase V16) and signed fold change relative to vehicle treated controls.
Green colouration denotes significant down-regulation whilst red colouration denotes significant up-regulation. Only miRNAs were the corrected
P value < 0.05 following analysis with DESeq (see materials and methods) are included within this analysis. Nomenclature: miR - mature miRNA,
miR* - minor product of mature miRNA, suffix (for example a, b, c) - denotes miRNAs with closely related mature sequences. (B) Five-order Venn
diagram demonstrating the number of miRNAs differentially regulated at each time point following AZM551248 administration. (C) Identification of
miRNAs clustered within 10Kb of each other on the canine genome. Clusters are denoted by the inclusion of a bracket. The direction of expression
change relative to vehicle treated control animals is denoted by the text colour (green down-regulated; red - up-regulated). Note the absence of
any clustered miRNAs following 8 days administration of AZM551248.
Figure 3 Reverse transcriptase real-time PCR verification of expression changes in canine miRNAs miR-200c, miR-31, miR-196a, miR-21,
miR-382 and miR-885 (panels A - F respectively). Data are mean relative expression units, controlled for reverse transcription efficiency and
normalised to miR-191, in cervical subcutaneous tissue following administration of vehicle (control) or MMPi for 4, 8, 11, 14 and 17 days + S.E.M
(n = 5). Data are analysed by one-way analysis of variance with Dunnett's post hoc test (comparing all experimental groups to vehicle)
where P < 0.05; * denotes P < 0.05, ** denotes P < 0.01 and *** denotes P < 0.001.
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in (1) Cellular Development, Embryonic Development,
Nervous System Development and Function, and (2)
Cardiovascular Disease, Cellular Movement, Haemato-
logical System Development and Function. The most
significant network highlighted an interplay between
miRNAs cfa-miR-144, cfa-miR-200* and cfa-miR-885,
the transcription factors Sp1, RelA and STAT1, and
marked the first elevation of transforming growth factor
beta transcript (TGFβ). It is interesting to note the up-
regulation of cfa-miR-144 at this time point and its poten-
tial role in the regulation of TGFβ via STAT1 repression
(Additional file 2).
Fourteen days administration of AZM551248 was as-
sociated with 14 dysregulated miRNAs compared with
vehicle treated controls. However, only three of these
dysregulated miRNAs were novel changes. This time
point was also associated with the significant up-
regulation of miR-21* (the minor product). Pathway ana-
lysis (comprising 14 miRNAs and 2509 mRNAs) revealed
the most significant changes to be associated with (1)
Post-translational Modification, Protein Folding, Cell
Cycle and (2) Connective Tissue Disorders, Dermato-
logical Diseases and Conditions. As with previous time
points, the transcription factors SP1, RelA and STAT1
were shown to interact extensively with these gene
networks, but miRNA involvement was not evident
(Additional file 2).
Seventeen days administration of AZM551248 was as-
sociated with 42 dysregulated miRNAs compared with
vehicle treated controls, of these 23 were novel changes.
Of particular interest were pro-fibrotic miRNAs miR-
199 and miR-382 which were significantly up-regulated
Figure 4 The top two scoring gene-networks (A and C) of dysregulated miRNAs and mRNAs, and associated biological functions (B
and D) in response to 4 days administration of MMPi as determined by Ingenuity Pathway Analysis. 4A and 4C - Data are mean fold
change represented graphically - green colouration denotes significant down-regulation whilst red colouration denotes significant up regulation
(P < 0.05). Arrows between molecules denote a stimulatory effect and blocked arrows denote a suppressive effect. Note: Transcription factors Sp1,
RelA, and STAT1 are included due to their association with gene changes involved in the development of MMPi induced fibrodysplasia. Network
score = −log (Fishers Exact Test result); Molecule Count refers to the number of molecules included within the network for which expression data
is available (miRNA or mRNA). 4B and 4D - Data are calculated P values (−Log) determined by the Fishers Exact Test for the most significant
biological functions associated with the top two scoring gene networks. Significance was accepted were P < 0.05 (−Log P > 1.301) as shown by
the threshold line in orange.
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(Figure 2A), and anti-inflammatory miR-335 which was
significantly down-regulated. Pathway analysis (compris-
ing 42 miRNAs and 2947 mRNAs) revealed the most
significant differential gene regulation to be associated
with (1) Amino Acid Metabolism, Cell Morphology, Cel-
lular Compromise and (2) Skeletal and Muscular System
Development, Cell to Cell Signalling (Additional file 2).
These gene networks centred on miRNAs cfa-miR-203
and cfa-miR-200a* respectively, highlighting a variety of
interactions between these miRNAs and the dysregulated
mRNAs identified previously. It is interesting to note that
Sp1, RelA and STAT1 involvement was absent at this time
point (within the most significant gene networks)
(Additional file 2) suggesting that the role of these
transcription factors may be related to the initiating events
in fibrodysplasia rather than disease progression.
Candidate tissue-based miRNA biomarkers of cervical
subcutaneous Fibrodysplasia
In addition to revealing the interesting possibility that
miRNAs may be involved in the initiation and progres-
sion of fibrodysplastic changes, the potential of these
small non-coding RNAs to function as tissue-based bio-
markers of the incidence or severity of such changes was
also investigated. Raw sequencing read counts for each
animal were normalised as previously described and
compared with both the histological score and plasma
PIIINP concentration (see Figure 1). Only miRNAs pre-
viously identified as significantly regulated were included
in this analysis (Figure 2A). Correlation with plasma
PIIINP concentration was used to filter the most signifi-
cant associations given that this data was continuous in
nature (as opposed to the discrete histological scores),
and has been show to correlate highly with the histo-
pathological findings (r = 0.73).
MicroRNAs cfa-miR-382, cfa-miR-380, cfa-miR-199,
cfa-miR-223 and cfa-miR-21 (including its less abundant
product cfa-miR-21*) were most strongly positively asso-
ciated with plasma PIIINP concentration (r = 0.53, 0.50,
0.49, 0.47, and 0.46 respectively). It is interesting to note
that cfa-miR-21 and cfa-miR-21* were significantly ele-
vated as early as day 11 at which point the most signifi-
cant pathological changes first became apparent, and
increased in expression as time progressed (and the
mean histopathological score and plasma PIIINP con-
centration increased). All other positively correlated
miRNAs were only significantly elevated from day 14
(cfa-miR-223) or day 17 (cfa-miR-382, cfa-miR-380 and
cfa-miR-199) despite appearing to be more closely asso-
ciated with plasma PIIINP concentration.
Moderate inverse correlations with plasma PIIINP
concentration were found with microRNAs cfa-miR-885,
cfa-miR-375, cfa-miR-211, cfa-miR-200c*, and cfa-miR-
182 (r = −0.36, -0.34, -0.27, -0.25, and −0.25 respect-
ively). MicroRNA cfa-miR-885 expression was signifi-
cantly decreased from 11 days whereas the remainder of
these miRNAs were first significantly decreased at day
17 (Figure 2A). Results of the 10 most highly correlated
miRNAs are included within Table 1.
In order to further validate the potential of the identi-
fied miRNAs as novel tissue-based biomarkers of FD, re-
verse transcriptase real-time miRNA-PCR assays were
obtained for candidate biomarkers miR-21, miR-382 and
miR-885. These were selected on the basis of their high
level of correlation with evidence of FD, and the avail-
ability of experimentally validated assays for the canine.
Receiver operator curve (ROC) analysis was performed
and area under the curve (AUC) values computed to as-
certain the ability of each prospective biomarker to cor-
rectly identify diseased and disease-free animals [19].
Table 1 Correlation of miRNA expression, plasma PIIINP concentration and histological evidence of FD




First detection of significant
regulation (Study Day)
cfa-miR-382 0.53 0.28 Day 17
cfa-miR-380 0.50 0.29 Day 17
cfa-miR-199 0.49 0.25 Day 17
cfa-miR-223 0.47 0.31 Day 14
cfa-miR-21 0.46 0.43 Day 11
cfa-miR-885 −0.36 −0.52 Day 11
cfa-miR-375 −0.34 −0.48 Day 17
cfa-miR-211 −0.27 −0.47 Day 17
cfa-miR-200c* −0.25 −0.42 Day 17
cfa-miR-182 −0.25 −0.50 Day 17
Correlation of miRNA expression in the cervical subcutaneous tissue with plasma PIIINP concentration and histological evidence of fibrodysplasia. Data are r values
for the top 10 most highly correlated miRNAs. This analysis was limited to those miRNAs previously identified as being significantly differentially expressed by
global miRNA sequencing where P< 0.05 following FDR correction (N = 24).
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The ability of these potential biomarkers to discriminate
between the various severities of FD was not examined
due to the limited number of cases in each category.
MicroRNA-21 (miR-21) expression showed the highest
level of discrimination with an AUC value of 0.97, whilst
microRNAs miR-382 and miR-885 reported AUC values
of 0.89 and 0.86 respectively. As a benchmark, the clas-
sical biomarker PIIINP reported an AUC value of 0.91.
Results of the ROC analysis are presented in Figure 5
(panels A - C) and ranked expression values of each
biomarker and histopathological grade presented in
(panels D - F) with the suggested cut-off values denoted
by a red line.
Discussion
The purpose of this study was to further explore the mo-
lecular events surrounding the initiation and progression
of AZM551248-induced fibrodysplasia (FD) in the ca-
nine. A detailed histopathological report of the changes
associated with FD in this study was published first in
Figure 5 Receiver operator curve analysis of candidate biomarkers miR 21, miR-382 and miR-885 (panels A - C respectively). Data are
normalised expression values generated by duplicate miRNA PCR reactions, controlled for reverse transcription efficiency and normalised to miR-
191. Animals were grouped into those without any histological evidence of FD (n = 16) and those with histological evidence of FD at any grade
(n = 13). MicroRNA-21 (miR-21) was predictive of FD incidence with a sensitivity of 92.31% and specificity of 93.75% (AUC = 0.97). MicroRNAs-382
(miR-382) and miR-885 revealed similar predictive abilities with sensitivity and specificity scores of 69.23% and 93.75% respectively (AUC = 0.89
and 0.86 respectively). Sensitivity and specificity are displayed graphically by the green line. The orange line denotes the line of identity which
highlights the shape of the curve should the biomarker offer no discrimination between control and cases. Panels D - F display corresponding
expression values for each individual animal ranked from the lowest to the highest expression value. Incidence and severity of FD in the cervical
subcutaneous tissue is denoted by the colour of each data point; Grey Circles - no evidence of FD, Green Circles - mild FD; Orange Circles -
moderate FD; Red Circles - severe FD. The cut-off value at which maximum sensitivity and specificity is obtained for each biomarker is marked by
a red bar (above threshold for miRs 21 and 382, and below threshold for miR-885).
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2009 [9] and described a phased onset of FD in the cer-
vical subcutaneous tissue following 11 days administra-
tion of AZM551248. More recently, an analysis of the
changes in messenger RNA (mRNA) expression and in
MMP activity following AZM551248 administration was
published [15]. The current manuscript builds upon pre-
vious work by investigating the role of microRNAs
(miRNAs) during the initiation of FD and furthermore,
considers their potential as novel tissue-based bio-
markers of FD.
Of the 13 miRNAs dysregulated at study day 4, 7 were
found to be members of the miR-200 family which has
been extensively investigated and its attenuation in ex-
pression implicated in the transition of epithelial cells to
a mesenchymal phenotype [20] in various mammalian
systems. Epithelial to mesenchymal transition (EMT) is
a biological process that allows epithelial cells to
undergo various biochemical changes to assume the
characteristics of a mesenchymal cell [21]. EMT is
categorised into three separate processes depending on
when it occurs; type I EMT occurs during embryogen-
esis and mediates the transition from primitive epithelia
to a mesenchymal phenotype, type II is associated with
organ fibrosis [22,23] and mediates the transition from
epithelial cells to fibroblasts [24], whilst type III is linked
with cancer progression and metastasis [21]. Given the
histological findings reported, and the significant down-
regulation of all members of the miR-200 family it is
plausible that MMPi administration induces type II
EMT; the molecular signature of which is apparent from
just 4 days administration. Attenuation of miR-200 fam-
ily members has been reported in various fibrotic path-
ologies including those of the lung ([23], kidney [25] and
gastrointestinal tract [26]. Eight days of MMPi adminis-
tration was associated with limited histological changes
and this was reflected by the appearance of just two new
miRNA perturbations, both of which corresponded to
the minor (star) products of miR-34c and miR-497
respectively.
Eleven days administration of AZM551248 was associ-
ated with the first histological evidence of FD and also
marked the first appearance of elevated TGFβ transcript,
consistent with the detection of immuno-reactive TGFβ
in activated fibroblasts [9], and in the plasma [15]. Day
11 marked the appearance of cfa-miR-21 as the most
highly expressed miRNA. Prior to this time point, miR-
145 was detected as the most abundant miRNA in the
cervical subcutaneous tissue (however its expression
remained unchanged by treatment). MicroRNA-145
(miR-145) expression in the dermal tissues is associated
with the regulation of melanogenesis [27]. MicroRNAs
miR-133a/b have been experimentally verified as partak-
ing in the negative regulation of TGFβ and connective
tissue growth factor (CTGF) signalling during fibrosis
[28,29] and are therefore reported as "anti-fibrotic" fac-
tors. Conversely, miR-21 is reported to have the opposite
effect, stimulating TGFβ signalling by both the canonical
and non canonical routes [30]. On balance, it appears
that miR-133a/b and miR-21 act co-operatively to regu-
late TGFβ signalling, with the drive for positive regula-
tion of TGFβ signalling by miR-21 overcoming the
negative regulation by miR-133a/b at this time. The sig-
nificant elevation of miR-21, and its apparent increase
coincident with the progression of FD also adds further
weight to the hypothesis that MMPi induces epithelial to
mesenchymal transition. The expression of miR-21 has
been reported previously as an acquired marker of EMT
[24] and tissue miR-21 expression was in fact identified
as a sensitive and specific biomarker of fibrodysplastic
change in this study (Figure 5). Moreover, two further
transcriptional regulators indicative of EMT, Snail and
Twist [24], were also elevated at the transcript level in
these study animals (> 2 fold, P < 0.05 from day 14) [15].
At day 14, dysregulation of three novel miRNAs was
noted. MicroRNA-223 (miR-223) has been reported to par-
take in the regulation of the acute inflammatory response
[31,32] which is pertinent given that marked inflammatory
cell infiltration was reported in the histological findings
around this study time point. The down-regulation of miR-
203 is also of interest at this time given its repression is
reported in several models of EMT [33]. Finally, this time
point was also associated with the significant up-regulation
of miR-21* (the minor product), suggesting marked tran-
scription of the miR-21 pre-miRNA transcript. Seventeen
days administration of AZM551248 was associated with
the up-regulation of pro-fibrotic miRNAs miR-199 and
miR-382 (Figure 2A), and down-regulation of anti-
inflammatory miR-335. MicroRNA miR-199 is reported
to induce extracellular matrix synthesis via stimulation of
the calcineurin signalling pathway [34,35], whilst miR-382
is reported to induce EMT by decreasing protection
against mitochondrial oxidative stress [36]. Again, these
miRNA changes appear to support the hypothesis of
AZM551248-induced EMT, and the histological findings
of increased ECM production.
Considering all of the available data, it is apparent that
several pro-EMT factors including growth factors, tran-
scriptional regulators and miRNAs are modulated from
as early as 4 days administration of the broad spectrum
MMPi AZM551248. These appear to orchestrate a se-
quence of signalling events resulting in the progressive
development of FD. The following hypothesis is
presented schematically in Figure 6. Around the same
time as the transcription factors Sp1, STAT1 and RelA
(and the proteases DPP4 and Cathepsin K) were found
to be up-regulated (day 4), significant down-regulation
of the miR-200 family was present. Transcription factor
Sp1 is predicted to be directly targeted by the miR-200
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Figure 6 Summary of the main histopathological and signalling events associated with AZM551248 administration. (A) Summary of the
main events associated with MMPi administration. Histopathological findings are shown below the bar, whilst important changes in signalling
pathways and miRNA expression are shown above the bar. (B) The cyclic relationship between miR-200 attenuation, transcription factor activation
and TGFβ production. Up-regulated factors are denoted in red, down-regulated factors in green, whilst factors not directly measured in this study
appear in white. Note: below the bar adapted from (Tugwood, Kelsall et al. 2012).
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family, suggesting that attenuation of the miR-200 family
may directly contribute to the up-regulation of Sp1 and
STAT1 (in-directly via Sp1). These molecular changes
may also offer some explanation for the increase in
TGFβ noted in response to MMPi administration. It has
been shown that TGFβ-2 is directly targeted by miR-141
/miR-200a, suggesting that attenuation of the miR-200
family may induce TGFβ signalling [37] through reduced
inhibition. This loss of miRNA mediated repression
would be in addition to the stimulation of TGFβ by
STAT1. As MMPi progressed, miR-21 expression in-
creased dramatically, the first significant changes being
present from 11 days administration. MicroRNA-21
(miR-21) has been found to stimulate both the canonical
and non-canonical TGFβ signalling pathways, offering a
third route of TGFβ stimulation [34,35].
Given the apparent significance of miR-200 family at-
tenuation following 4 days administration of MMPi, we
sought clarity on how this family were themselves tran-
scriptionally regulated. The transcription factor ZEB1 has
been shown to repress miR-200c/141, and miR-200b/200a/
429 promoter regions in several cancers [38], at which time
an inverse relationship between miR-200 and ZEB expres-
sion was noted. Moreover, BMPs and TGFβ (induced in
this study) are reported to activate ZEB transcription fac-
tors [39] forming a TGFβ/ZEB/miR-200 signalling network
Figure 6B. Of particular interest is the finding that contin-
ued expression of TGFβ leads to the hypermethylation of
miR-200 family promoter regions. This hypermethylation
is found to increase with TGFβ exposure, and results in the
attenuation of miR-200 expression [40]. This finding pre-
sents a further, ZEB independent method by which
prolonged TGFβ expression may be self perpetuated via
miR-200 family attenuation.
Moving forward, we highlight the need to further in-
vestigate the TGFβ/ZEB/miR-200 signalling network,
and the specific interactions between miRNAs and the
various transcription factors discussed herein (SP1, RelA
and STAT1). To further study the TGFβ/ZEB/miR-200
signalling network, we propose a series of in vitro exper-
iments conducted in an appropriate skin cell line. The
proposed system would permit the over expression of
TGFβ and/or various miR-200 family members (either
independently or as a family) and would be amenable to
methylation assessment. To further elucidate the inter-
actions between miRNAs and the major transcription
factors, we propose an additional in vitro experiment in
which individual miRNAs could be over expressed and
the resulting effects on both transcription factor mRNA
and protein determined.
Conclusions
We have shown that significant attenuation of the miR-
200 family is noted in response to MMPi administration
in the canine. Using global mRNA and miRNA data, we
present a working hypothesis whereby attenuation of
miR-200 contributes to the activation of several tran-
scription factors including Sp1, STAT1 and RelA. Using
pathway analysis, we have suggested a link between the
attenuation of the miR-200 family, and the appearance
of TGFβ at the transcript and protein levels from day
11. Furthermore, we have highlighted a potential route
for maintaining this TGFβ up-regulation via a TGFβ/
ZEB/miR-200 signalling network, and by the de novo re-
versible hypermethylation of the miR-200 family pro-
moter region.
Methods
AZM551248 In vivo study
The AZM551248 time-course study design and
resulting histopathological changes have been reported
in detail elsewhere [9,15]. Briefly, 30 female beagle
dogs, around 12 months of age were randomly
assigned to six experimental groups as described in
Table 2. Animals were dosed orally once daily either with
vehicle alone (0.5%w/v hydroxypropyl methylcellose/0.1%
polysorbate 80, 5ml/kg), or with vehicle plus 20mg/kg/day
AZM551248 [15]. Following termination, a histopatho-
logical analysis was carried out on subcutaneous tissue,
dermal skin, synovium, tendon and muscle from several
sites. In addition, dermal and subcutaneous tissue samples
from the left and right abdomen, left and right dorsal cer-
vical and lumbar regions, and adjacent to the calcaneal
tendon and gastrocnemius muscle with associated tendon
were also taken. These samples were snap frozen in liquid
nitrogen for RNA analysis; the analysis described herein is
confined to the dorsal cervical subcutaneous skin. Details
of the histopathological analysis are described in detail
elsewhere [9]. Animal experiments underwent local ethical
review and were conducted in full compliance with UK
Home Office guidelines.
Determination of plasma PIIINP concentration
Whole blood was drawn into EDTA containing tubes
and plasma prepared by centrifugation. Samples were
drawn on the day of termination at stored at −80°C prior
to analysis. Canine plasma PIIINP was determined in







1 1–5 Vehicle 17 0
2 6–10 AZM551248 4 20
3 11–15 AZM551248 8 20
4 16–20 AZM551248 11 20
5 21–25 AZM551248 14 20
6 26–30 AZM551248 17 20
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duplicate by radioimmunoassay (Orion Diagnostica)
against a human PIIINP standard curve supplied in the
kit.
RNA preparation
Total RNA was isolated from dorsal cervical subcutane-
ous skin tissue using the miRNeasy extraction kit
(Qiagen), following the manufacturers standard protocol.
RNA was quantitated using a NanoDrop ND-1000 spec-
trophotometer (Thermo Fisher) and quality was assessed
using the Agilent RNA 6000 Nano Kit (Agilent). In order
to enrich for small RNA molecules, total RNA samples
were passed through PureLink miRNA extraction col-
umns (Invitrogen) according to the manufacturers
standard instructions. The resulting enriched RNA sam-
ples were then assessed using the Agilent Small RNA Kit
(Agilent) and the percentage of small RNA (10–40 nu-
cleotides) determined relative to the mass of total RNA.
Preparation of SOLiD sequencing libraries
Global miRNA expression profiling of the cervical sub-
cutaneous tissue of four randomly selected animals from
each experimental group (n = 4, N = 24) was performed
by next-generation sequencing using the SOLiD 4.0 sys-
tem (Applied Biosystems). Briefly, 5ng of enriched RNA
was ligated with SOLiD sequencing adapters overnight
and reverse transcribed to synthesise complementary
DNA (cDNA). The resulting cDNA was resolved on 10%
v/v TBE-urea gels against a 10bp ladder (Invitrogen) and
the 60-80nt region, containing miRNA-sized RNA spe-
cies with adapters, excised. Gel slices were amplified by
in-gel PCR using a common 5’ primer (SOLiD 5'), and a
specific 3’ primer (SOLiD Barcodes 1–24) to incorporate
a molecular barcode into each sample so as to permit
sample multiplexing. Equimolar amounts of each library
were pooled at this stage, and template preparation
performed using the SOLiD EZ-Bead system and E80
emulsion PCR reagents (PN 4452722). Sequencing was
performing in-house using 35 base pair (bp) chemistry
(Applied Biosystems) and raw sequencing read counts
were mapped to miRBase V16.0 (Canis familiaris),
normalised to account for the varying sequencing depths
between samples, and differential expression inferred
using the DESeq script for R statistical language.
Bioinformatic analysis
Primary processing of the raw sequencing data to remove
adapter sequences and de-convolute the 24 multiplexed
samples was undertaken during the sequencing process
using BioScope software (Applied Biosystems). Following
primary processing, raw sequencing reads were exported
in colour-space fasta (csfasta) format into CLC Genomics
Workbench (CLC). An "extract and count" routine was
utilised to condense the millions of sequencing reads into
a tally table of each nucleotide sequence, and the number
of times that particular sequence was encountered. A sep-
arate tally table was produced for each of the 24 animals.
Reads shorter than 15 nucleotides and longer than 35 nu-
cleotides were filtered at this stage. Following parsing to
remove superfluous data columns, the resulting tally ta-
bles comprising the miRNA name and count were
imported into miRanalyzer V0.2 [41]. Reads were mapped
to the Canis familiaris genome (CanFam2) and to miRBase
version 16.0 permitting one mismatch between the se-
quencing reads and each index. Reads mapping to known
miRNAs were counted and a relative expression value de-
termined by dividing the number of reads mapping to
each particular miRNA by the total number of reads
mapped. Differential expression and P value estimation
was performed using the DESeq package for R statistical
language which models count-based data with negative bi-
nomial distributions and uses the method of Benjamini
and Hochberg to control for type I error [42].
Pathway analysis
Biological interpretation of the dysregulated miRNAs at
each time point was undertaken using the Ingenuity
Pathway Analysis (Ingenuity Systems) database accessed
on June 2012. miRNAs were identified by their official
sequence names (for example cfa-miR-21 for canine ma-
ture microRNA 21) and regulation was identified by the
fold change values provided by DESeq. Only miRNAs
with estimated P values of <0.05 following false discov-
ery rate correction were included within each analysis.
For the integrated analysis of miRNA and messenger
RNA (mRNA) expression data, lists of differentially
expressed mRNAs previously published by Tugwood
and colleagues were utilised. mRNAs were identified by
their official gene symbol, and only genes with fold
changes > 2 and where P < 0.05 (students two-tailed t-
test) were included in the analysis. To prepare the
concatenated miRNA/mRNA input files for IPA, the two
sources of significantly regulated molecules (miRNAs
and mRNAs) were combined into a standard text file
(.txt) using Excel 2007 (Microsoft). Fields included the
gene identifier (official gene symbol for mRNA and of-
ficial sequence name for miRNAs) and the signed fold
change. A comprehensive list of gene expression
changes at each time point are included within
Tugwood et al. [15].
Quantitative PCR analysis
Complementary DNA was synthesised from 1μg total
RNA using the qScript miRNA cDNA synthesis kit
(QuantaBio) in a total reaction volume of 20μl. Prior to
reverse transcription, samples were spiked with 5nM
synthetic miRNA (cel-miR-39-3p) to control for varying
reverse transcription efficiencies. Each PCR reaction
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consisted of 5μl SYBR Green master mix (QuantaBio),
0.2μl miRNA Assay (Integrated DNA Technologies),
0.2μl Universal PCR Primer (QuantaBio), 2.6μl water
and 2μl template cDNA (diluted 1:100 in 1 x TE). PCR
was performed using a RotorGene Q thermocycler
(Qiagen) with an initial denaturation step at 95°C for 2
minutes followed by 40 cycles of 95°C 5 seconds, 60°C
15 seconds and 70°C 15 seconds. The following miRNA
Assays sourced from Integrated DNA Technologies were
utilised herein (HSMIR-0031, HSMIR-0196A, HSMIR-
0141, HSMIR-0885, MMIR-382*, HSMIR-0021, HSMIR-
0191, HSMIR-0200C). Assay compatibility with the canine
was validated by comparing the miRNA assay primer se-
quences with the respective canine miRNA sequence
using publically available miRNA data (miRBase Version
16). All PCR data was normalised to the median expres-
sion of synthetic miRNA cel-miR-39-3p to control for re-
verse transcription efficiency [43] and then normalised to
miR-191 which was found to be invariant across the vari-
ous time points (there were no statistically significant
changes between the experimental groups as determined
by one-way analysis of variance).
Statistical analyses
Analysis of PCR Data - all normalised PCR data were
analysed by one-way analysis of variance with Dunnett's
post hoc test (comparing all experimental groups to ve-
hicle) performed where P < 0.05.
Correlation Analysis - assessment of correlation be-
tween the significantly regulated miRNAs (as deter-
mined by miRNA-seq) and plasma PIIINP concentration
was determined by the method of Pearson using
GraphPad 5.0 software (Prism) (N = 24).
Receiver Operator Curve Analysis - ROC analysis was
performed using normalised miRNA data generated by
validated canine PCR primers. ROC analysis was
performed on data from all study time points and area
under the curve (AUC) values were computed using
GraphPad 5.0 software (Prism) as an index of discrimin-
atory power. An AUC value of 0.5 denotes no ability to
correctly identify diseased and disease-free subjects,
whilst an AUC value of 1.0 denotes perfect decimation
between the two groups of interest [19].
Assessment of Significant Gene Networks - networks of
molecules identified by IPA were ranked based upon
their respective "Network Score" as defined as the -log
Fishers Exact Test result. Network scores are included
within all gene network diagrams.
Supporting data
A comprehensive list of all miRNAs modulated in re-
sponse to AZM551248 are presented in the supplemen-
tary file (Additional file 1.xls).
The top two gene-networks of dysregulated miRNAs
and mRNAs in response to 8, 11, 14 and 17 days admin-
istration of MMPi are presented in the supplementary
file (Additional file 2.pdf ).
Additional files
Additional file 1: A comprehensive list of all miRNAs modulated in
response to AZM551248 administration as determined by miRNA-seq.
Additional file 2: The top two scoring gene-networks of miRNAs
and mRNAs dysregulated in response to 8, 11, 14 and 17 days
administration of AZM551248.
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